[1]Patent:WO2010/31182,2010,A1.Locationinpatent:Page/Pagecolumn17
[2]JournalofOrganicChemistry,2012,vol.77,p.2299-2309
1218918-62-7
[1]BioorganicandMedicinalChemistryLetters,2011,vol.21,p.288-293
[1]BioorganicandMedicinalChemistryLetters,2011,vol.21,p.288-293
[1]JournalofOrganicChemistry,2012,vol.77,p.2299-2309
[1]JournalofOrganicChemistry,2012,vol.77,p.2299-2309
Title: UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study.
Journal: Clinical pharmacology and therapeutics 20120701
Title: CRTH2 antagonist MK-7246: a synthetic evolution from discovery through development.
Journal: The Journal of organic chemistry 20120302
Title: Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.
Journal: Journal of medicinal chemistry 20111027
Title: New indole amide derivatives as potent CRTH2 receptor antagonists.
Journal: Bioorganic & medicinal chemistry letters 20110601
Title: Azaindoles as potent CRTH2 receptor antagonists.
Journal: Bioorganic & medicinal chemistry letters 20110115
Title: Pharmacological characterization of MK-7246, a potent and selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells) antagonist.
Journal: Molecular pharmacology 20110101
Title: Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.
Journal: Bioorganic & medicinal chemistry letters 20110101
Title: Gervais FG, et al. Pharmacological characterization of MK-7246, a potent and selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells) antagonist. Mol Pharmacol. 2011 Jan;79(1):69-76.
Title: Gil MA, et al. Anti-inflammatory actions of Chemoattractant Receptor-homologous molecule expressed on Th2 by the antagonist MK-7246 in a novel rat model of Alternaria alternata elicited pulmonary inflammation. Eur J Pharmacol. 2014 Nov 15;743:106-16.
